Bayer launches Finerenone medication for CKD patients with type 2 diabetes https://ift.tt/Hx4sjab

Finerenone is different to existing CKD in T2D treatments. It acts by blocking mineralocorticoid receptor (MR) over activation, which is thought to contribute to CKD progression and cardiovascular damage.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/0yVrY7J
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.